Turnover: 45.3 million EUR (2022)
Country: France
Diagast has been producing and marketing immunohematology reagents and systems for blood typing for 30 years. Diagast's R&D center is home to groundbreaking innovations such as EM Technology in 2004 and M-Trap in 2012. Diagast also boasts a wide range of FDA-approved fermenters, giving it considerable production capacity.
Financial Data
DUNS: 343445375
Legal Name: DIAGAST
Address: 251 AV EUGENE AVINEE EURASANTE PARC, 59120 LOOS
Number of employees: Entre 200 et 249 salariés (2018)
Capital: 4 742 140 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2018 | 40 650 400 EUR | 2 391 044 EUR | 31/12/2018 | 12 |
| 2017 | 35 778 014 EUR | 2 366 541 EUR | 31/12/2017 | 12 |
| 2016 | 35 733 320 EUR | 2 193 907 EUR | 31/12/2016 | 12 |
| 2015 | 32 898 858 EUR | 1 836 107 EUR | 31/12/2015 | 12 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président | Bruno | MORINO | 62 |
Studies mentioning this company
The in vitro diagnostics market - France
Other companies mentioned:
- Roche Groupe
- Diagast
- Abbott Groupe
- Danaher
- Thermo Fisher Diagnostics
- Sebia
- BioMerieux Groupe
- Diagnostica Stago
- Biosynex
- Diagnostic Medical System DMS Groupe